Drug intelligence / Profile preview

NC-ACI

Development stage: Preclinical
Lead developer: Medlab Clinical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Sublingual

Overview

NC-ACI is a preclinical drug candidate being developed by Medlab Clinical (now Medlab Group) for the treatment of sarcopenia and the promotion of cellular biogenesis. The product utilizes Medlab's proprietary NanoCelle® technology, a sublingual nanoparticle delivery system that creates micellar structures to enhance the solubility and absorption of active pharmaceutical ingredients. NC-ACI consists of a repurposed generic pharmaceutical agent, the identity of which remains undisclosed, formulated for sublingual administration to trigger anabolic pathways and support cellular health in aging populations.

Beyond the preview

Go deeper on NC-ACI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC-ACI.

Explore the full profile